Company intelligence / Profile preview

Gendius

Alderley Edge, United Kingdomintellinn.co.za ↗

Ownership: Private
Development stage: Commercial

Overview

Intellin is an AI-powered digital health platform designed to help people with diabetes manage their condition by predicting risk of complications and providing personalized care recommendations. It uses patient data to identify those at highest risk for complications such as foot ulcers or cardiovascular events and guides both patients and clinicians in proactive disease management.

Therapeutic areas: OtherEndocrinology
Modalities: Non-pharmacological therapyDigital therapeuticDevice (mobile app/software platform)
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

Intellin

Commercial

Indications: Diabetes

Partnerships

NHS trusts in the UK for clinical validation/deployment.Academic collaborations with UK universities for research studies.

Beyond the preview

Go deeper on Gendius.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gendius.

Explore the full profile